Drug Safety, Parts 4-5

U.S. Government Printing Office, 1966 - Drugs

Exhibit 1Regulations pertaining to current good manufacturing prac	1444

CONTENTS 078	1447

Exhibit 2Organizational charts of the Food and Drug Administration	1454

Hearings held on Page	1505

Exhibit 4Subcommittee summary concerning FDA handling of labeling	1506

Exhibit 5Memorandum of telephone conversation between Mr C	1515

Exhibit 6Excerpts from establishment inspection report on Abbott	1533

Exhibit 7Excerpts from establishment inspection report on Abbott	1546

Letters statements etc submitted for the record	1909

Exhibit 6Letter from January 22 1966 Lancet concerning teratogenic	1919

MK665 ETHYNERONE	1953

DRUG ADVERTISING HEARINGS OF MAY 25 AND 26 1966	1966

Statement of George P Larrick Commissioner Food and Drug Adminis	1994

Exhibit 1Objections to proposed drug advertising regulations filed	2004

Exhibit 2Selected ads demonstrating some of the problems of prescrip	2022

Exhibit 3Prescription drug advertising casestype of action taken	2036

Exhibit 8Documents pertaining to situations in which mislabeled	1576

Exhibit 9Memorandum describing wire sent by Abbott to its field per	1588

Exhibit 10Memorandum of telephone conversations concerning alleged	1596

Exhibit 11Request to Washington by Chicago District for citation	1617

Exhibit 12Memorandum of telephone conversation between Elmer	1624

Exhibit 13Memorandum by James Nakada Division of Field Opera	1642

Exhibit 14Excerpt from Federal Food Drug and Cosmetic Act relat	1656

Exhibit 15Documents pertaining to reinspection at hospital where Page	1670

Exhibit 16Intraagency memorandum concerning label mixups occur	1685

Exhibit 17Memorandum by Dr Arthur Ruskin Deputy Director	1715

Exhibit 21Memorandum of telephone conversations on September 8	1736

Exhibit 23Memorandum of telephone conversations involving Mr Nevis	1798

Exhibit 25Statement of longdistance telephone calls from U S Food	1812

Exhibit 29Excerpts from report of inspection at Abbott Laboratories	1841

Hearings held on Page	1861

Exhibit 1List of INDs for DMSO submitted by sponsors other than Page	1901

Exhibit 4Letter from Acting Chief of FDAs Investigational Drug	1907

Exhibit 4FDA press release on seizure of Serax for false advertising	2042

Exhibit 5Ad for Measurin from the March 21 1966 issue of the Journal	2050

Exhibit 6Memorandum of conference between representatives of	2057

Exhibit 8Working agreement between FTC and FDA__	2087

Testimony	2090

Exhibit 9Summary of drug trade ad expenditures	2102

Exhibit 1Members of the FDA Advisory Committee on the Abuse	2138

Exhibit 3Correspondence between Chairman Fountain and former Com	2159

Exhibit 4Article from the New Republic May 14 1966 concerning dan	2169

Exhibit 6Draft of a paper on the therapeutic use of highdose LSD ses	2217

Exhibit 7Psychedelic Therapy a paper by Charles Savage M D	2232

Journal for the Study of Interper	2242

Appendix 1General_	2273

Appendix 2Material relating to part 2 of the hearings	2309

Appendix 4Material relating to part 4 of the hearings	2354

Belson J Joseph Food and Drug Officer Division of Case Supervision	2369

Title	Drug Safety, Parts 4-5 Drug Safety, United States. Congress. House. Committee on Government Operations
Author	United States. Congress. House. Committee on Government Operations
Publisher	U.S. Government Printing Office, 1966
Original from	the University of California
Digitized	5 Aug 2010

Export Citation	BiBTeX EndNote RefMan

Books